CYP4F11, an NRF2 Target Gene, Promotes Hepatocellular Carcinoma Cell Growth

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited effective treatments.
• Nuclear factor erythroid 2-related factor-2 (NRF2) pathway dysregulation is common in HCC, promoting tumor progression.
• Novel therapeutic targets are urgently needed for HCC management.

Purpose of the Study:

• To identify novel therapeutic targets in HCC.
• To investigate the role of NRF2 in HCC progression.
• To explore the functional significance of CYP4F11 in HCC.

Main Methods:

• Gene expression analysis in HCC patient cohorts.
• NRF2 target gene identification.
• In vitro studies on HCC cell lines to assess CYP4F11 function.
• Assessment of NRF2 inhibition and sorafenib combination therapy.

Main Results:

• CYP4F11 identified as a direct NRF2 target gene, upregulated in HCC.
• Elevated CYP4F11 expression correlates with NRF2 pathway activation in HCC.
• CYP4F11 promotes HCC cell proliferation and survival.
• Downregulation of CYP4F11 suppresses HCC growth and enhances sorafenib sensitivity.

Conclusions:

• The NRF2-CYP4F11 axis is a key driver of HCC progression.
• CYP4F11 is a potential therapeutic target for HCC.
• Targeting the NRF2-CYP4F11 pathway could enhance current HCC therapies like sorafenib.